Search results for "Targeting"

showing 10 items of 186 documents

E-beam crosslinked nanogels conjugated with monoclonal antibodies in targeting strategies

2017

Abstract Poly(N-vinyl pyrrolidone)-based-nanogels (NGs), produced by e-beam irradiation, are conjugated with monoclonal antibodies (mAb) for active targeting purposes. The uptake of immuno-functionalized nanogels is tested in an endothelial cell line, ECV304, using confocal and epifluorescence microscopy. Intracellular localization studies reveal a faster uptake of the immuno-nanogel conjugate with respect to the ‘bare’ nanogel. The specific internalization pathway of these immuno-nanogels is clarified by selective endocytosis inhibition experiments, flow cytometry and confocal microscopy. Active targeting ability is also verified by conjugating a monoclonal antibody which recognizes the αv…

0301 basic medicinemedicine.drug_classConfocalmedia_common.quotation_subjecthigh-energy irradiationClinical BiochemistryNG[object Object]02 engineering and technologyMonoclonal antibodyBiochemistryCell LineFlow cytometrylaw.invention03 medical and health sciencesConfocal microscopylawFluorescence microscopemedicineHumansInternalizationMolecular Biologymedia_commonradiation-engineeredDrug Carriersmedicine.diagnostic_testChemistrywound healing assay.antiβ3 integrin antibodyAntibodies MonoclonalPovidoneactive-targetingBiological Transport021001 nanoscience & nanotechnologyMolecular biologyNanostructures030104 developmental biologyTargeted drug deliverynanogelpoly(N-vinyl pyrrolidone)Biophysics0210 nano-technologyGelswound healing assayNanogelBiological Chemistry
researchProduct

A novel rationale for targeting FXI: Insights from the hemostatic microRNA targetome for emerging anticoagulant strategies

2021

Therapeutic targeting of blood coagulation is a challenging task as it interferes with the delicate balance of pro- and anticoagulant activities. Anticoagulants are employed in millions of thrombophilic patients worldwide each year. The treatment and prevention of venous thromboembolism has changed drastically. Traditional vitamin K antagonists are being replaced by direct oral anticoagulants (DOACs), which selectively target coagulation factors Xa or IIa. However for a growing population with comorbidities satisfying therapeutic options are still lacking and the quest for novel therapeutics continues. Recently, targeting factors XI or XII have emerged as new therapeutic strategies. As thes…

0301 basic medicinemedicine.drug_classPopulationVitamin kBioinformaticsTherapeutic targeting03 medical and health sciences0302 clinical medicinemicroRNAHumansMedicinePharmacology (medical)educationFactor XIPharmacologyHemostasiseducation.field_of_studybusiness.industryAnticoagulantAnticoagulantsThrombosisMicroRNAs030104 developmental biologyCoagulation030220 oncology & carcinogenesisHemostasisbusinessVenous thromboembolismPharmacology & Therapeutics
researchProduct

Virotherapy in Germany—Recent Activities in Virus Engineering, Preclinical Development, and Clinical Studies

2021

Virotherapy research involves the development, exploration, and application of oncolytic viruses that combine direct killing of cancer cells by viral infection, replication, and spread (oncolysis) with indirect killing by induction of anti-tumor immune responses. Oncolytic viruses can also be engineered to genetically deliver therapeutic proteins for direct or indirect cancer cell killing. In this review—as part of the special edition on “State-of-the-Art Viral Vector Gene Therapy in Germany”—the German community of virotherapists provides an overview of their recent research activities that cover endeavors from screening and engineering viruses as oncolytic cancer therapeutics to their cli…

0301 basic medicinemedicine.medical_treatmentGenetic enhancementvirus targetingMedizinReviewcombination therapychemistry.chemical_compoundDDC 570 / Life sciencesClinical trials0302 clinical medicineKlinisches ExperimentGermanyNeoplasmsMedicineimmunotherapy ; therapeutic transgene ; combination therapy ; Virustherapie ; clinical trials ; virus engineering ; oncolytic virus ; research in Germany ; virus targeting ; virotherapyOncolytic VirotherapyClinical Trials as Topicvirus engineeringKombinationstherapieQR1-5023. Good healthOncolytic VirusesInfectious Diseases030220 oncology & carcinogenesisImmunotherapyvirotherapyGenetic Engineeringresearch in GermanyMicrobiologyVirusViral vector03 medical and health sciencesImmune systemddc:570VirologyAnimalsHumanstherapeutic transgeneVirotherapyoncolytic virusbusiness.industryImmunotherapyVirologyOncolytic virusImmuntherapie030104 developmental biologychemistryVacciniabusinessViruses
researchProduct

Lipoproteins LDL versus HDL as nanocarriers to target either cancer cells or macrophages

2020

free open access article 31 p.; International audience; In this work, we have explored natural unmodified low- and high-density lipoproteins (LDL and HDL) as selective delivery vectors in colorectal cancer therapy. We show in vitro in cultured cells and in vivo (NanoSPECT/CT) in the CT-26 mice colorectal cancer model that LDLs are mainly taken up by cancer cells, while HDLs are preferentially taken up by macrophages. We loaded LDLs with cisplatin and HDLs with the heat shock protein-70 inhibitor AC1LINNC, turning them into a pair of “Trojan horses” delivering drugs selectively to their target cells as demonstrated in vitro in human colorectal cancer cells and macrophages, and in vivo. Coupl…

0301 basic medicinemedicine.medical_treatmentcisplatinlcsh:Medicineheat shock protein inhibitorCancer immunotherapy[CHIM.THER]Chemical Sciences/Medicinal ChemistrySpectrum Analysis RamanMiceDrug Delivery Systems0302 clinical medicineCancer immunotherapyChemistryRselective cell targetingGeneral Medicine3. Good healthLipoproteins LDLOncology030220 oncology & carcinogenesisMedicinecancer therapylipids (amino acids peptides and proteins)Colorectal NeoplasmsLipoproteins HDLResearch Articlemedicine.drug[CHIM.THER] Chemical Sciences/Medicinal ChemistryLipoproteinsTherapeuticsCell Line03 medical and health sciencesImmune systemIn vivoCell Line TumormedicinevectorizationAnimalsHumansCisplatinMacrophageslcsh:RCancermedicine.diseaseColorectal cancerIn vitro030104 developmental biologyCancer cellCancer researchNanocarriers[SDV.MHEP]Life Sciences [q-bio]/Human health and pathology
researchProduct

DNA folds threaten genetic stability and can be leveraged for chemotherapy

2020

International audience; Damaging DNA is a current and efficient strategy to fight against cancer cell proliferation. Numerous mechanisms exist to counteract DNA damage, collectively referred to as the DNA damage response (DDR) and which are commonly dysregulated in cancer cells. Precise knowledge of these mechanisms is necessary to optimise chemotherapeutic DNA targeting. New research on DDR has uncovered a series of promising therapeutic targets, proteins and nucleic acids, with application notably via an approach referred to as combination therapy or combinatorial synthetic lethality. In this review, we summarise the cornerstone discoveries which gave way to the DNA being considered as an…

0303 health sciencesDna targetingDNA damageGenetic stabilityCancer cell proliferationChemical biologySynthetic lethalityComputational biology[CHIM.THER]Chemical Sciences/Medicinal ChemistryBiochemistry Genetics and Molecular Biology (miscellaneous)Biochemistry03 medical and health scienceschemistry.chemical_compound0302 clinical medicinechemistryChemistry (miscellaneous)030220 oncology & carcinogenesis[SDV.BBM.GTP]Life Sciences [q-bio]/Biochemistry Molecular Biology/Genomics [q-bio.GN]Cancer cellMolecular BiologyDNA030304 developmental biology
researchProduct

Alternative NF-κB signaling regulates mTEC differentiation from podoplanin-expressing precursors in the cortico-medullary junction

2015

The thymic epithelium forms specialized niches to enable thymocyte differentiation. While the common epithelial progenitor of medullary and cortical thymic epithelial cells (mTECs and cTECs) is well defined, early stages of mTEC lineage specification have remained elusive. Here, we utilized in vivo targeting of mTECs to resolve their differentiation pathways and to determine whether mTEC progenitors participate in thymocyte education. We found that mTECs descend from a lineage committed, podoplanin (PDPN)-expressing progenitor located at the cortico-medullary junction. PDPN(+) junctional TECs (jTECs) represent a distinct TEC population that builds the thymic medulla, but only partially supp…

0303 health scienceseducation.field_of_studyImmunologyPopulationGene targetingBiologyCell biology03 medical and health sciencesThymocyte0302 clinical medicinePodoplaninImmunologyImmunology and AllergyCentral toleranceProgenitor celleducationPDPN030304 developmental biology030215 immunologyProgenitorEuropean Journal of Immunology
researchProduct

Nanoparticles of a polyaspartamide-based brush copolymer for modified release of sorafenib: In vitro and in vivo evaluation.

2017

Abstract In this paper, we describe the preparation of polymeric nanoparticles (NPs) loaded with sorafenib for the treatment of hepatocellular carcinoma (HCC). A synthetic brush copolymer, named PHEA-BIB-ButMA (PBB), was synthesized by Atom Trasnfer Radical Polymerization (ATRP) starting from the α-poly( N -2-hydroxyethyl)- d , l -aspartamide (PHEA) and poly butyl methacrylate (ButMA). Empty and sorafenib loaded PBB NPs were, then, produced by using a dialysis method and showed spherical morphology, colloidal size, negative ζ potential and the ability to allow a sustained sorafenib release in physiological environment. Sorafenib loaded PBB NPs were tested in vitro on HCC cells in order to e…

3003MaleHepatocellular carcinomamedicine.medical_treatmentPharmaceutical Science02 engineering and technologyATRPPharmacology01 natural sciencesDrug Delivery SystemsCopolymerChemistryATRP; Hepatocellular carcinoma; Sorafenib; Tumor targeting; α-Poly(N-2-hydroxyethyl)-DL-aspartamide; 3003Liver NeoplasmsSorafenib021001 nanoscience & nanotechnologyDrug delivery0210 nano-technologymedicine.drugSorafenibNiacinamideCarcinoma HepatocellularCell SurvivalRadical polymerizationIntraperitoneal injectionL-aspartamideMice NudeAntineoplastic AgentsEnhanced permeability and retention effect010402 general chemistryPolymethacrylic AcidsIn vivoCell Line TumormedicineAnimalsHumansneoplasmsProtein Kinase InhibitorsPhenylurea Compoundstechnology industry and agriculturedigestive system diseasesIn vitro0104 chemical sciencesDrug LiberationTumor targetingDelayed-Action PreparationsBiophysicsα-Poly(N-2-hydroxyethyl)-DNanoparticlesα-Poly(N-2-hydroxyethyl)-DL-aspartamidePeptidesJournal of controlled release : official journal of the Controlled Release Society
researchProduct

Site-specific DBCO modification of DEC205 antibody for polymer conjugation

2018

The design of multifunctional polymer-based vectors, forming pDNA vaccines, offers great potential in cancer immune therapy. The transfection of dendritic immune cells (DCs) with tumour antigen-encoding pDNA leads to an activation of the immune system to combat tumour cells. In this work, we investigated the chemical attachment of DEC205 antibodies (aDEC205) as DC-targeting structures to polyplexes of P(Lys)-b-P(HPMA). The conjugation of a synthetic block copolymer and a biomacromolecule with various functionalities (aDEC205) requires bioorthogonal techniques to avoid side reactions. Click chemistry and in particular the strain-promoted alkyne-azide cycloaddition (SPAAC) can provide the req…

540 Chemistry and allied sciencesRAFT polymerizationpDNA polyplexvaccinationbioorthogonal chemistryArticleDEC205 antibodylcsh:QD241-441strain-promoted alkyne-azide cycloaddition (SPAAC)lcsh:Organic chemistry540 Chemiecancer immune therapydendritic cells (DCs)targeting
researchProduct

Cytochrome P450 regulation by hepatocyte nuclear factor 4 in human hepatocytes: A study using adenovirus-mediated antisense targeting

2001

Abstract Hepatocyte nuclear factor 4 (HNF4) is a member of the nuclear receptor super-family that has shown activating effects on particular cytochrome P450 (CYP) promoters from several species. However, its role in the regulation of human CYPs in the liver is still poorly understood, as no comprehensive studies in human-relevant models have been performed. In the present study, we have investigated whether HNF4 plays a general role in the expression of 7 major CYP genes in primary cultured human hepatocytes. To this end, we developed an adenoviral vector for efficient expression of HNF4 antisense RNA. Transduction of human hepatocytes with the recombinant adenovirus resulted in a time-depe…

AdultMaleGene ExpressionBiologymedicine.disease_causeAdenoviridaeCytochrome P-450 Enzyme SystemGene expressionmedicineHumansRNA MessengerTranscription factorCells CulturedAgedMessenger RNAExpression vectorHepatologyBasic Helix-Loop-Helix Leucine Zipper Transcription FactorsMiddle AgedOligonucleotides AntisensePhosphoproteinsMolecular biologyAntisense RNADNA-Binding Proteinsbody regionsAdenoviridaeHepatocyte Nuclear Factor 4LiverHepatocyte nuclear factor 4Nuclear receptorGene TargetingHepatocytesRNAFemaleTranscription FactorsHepatology
researchProduct

Folate-mediated targeting of polymeric conjugates of gemcitabine.

2005

The synthesis of two new macromolecular prodrugs for active tumor targeting was set up. Gemcitabine (2'-deoxy-2',2'-difluorocytidine) was conjugated to alpha,beta-poly(N-2-hydroxyethyl)-DL-aspartamide (PHEA) through succinyl or diglycolyl hydrolysable spacers. The targeting agent folic acid was attached to the macromolecular backbone through the aminocaproic spacer. The two conjugates [PHEA-(5'-succinylgemcitabine)-1'-carboxypentyl-folamide and PHEA-(5'-diglycolyl-gemcitabine)-1'-carboxypentyl-folamide], were purified and extensively characterised by spectroscopic (UV, IR and NMR) and chromatographic analyses to determine the correct chemical structure, the purity degree and the reaction yi…

Antimetabolites AntineoplasticTime FactorsStereochemistryCell SurvivalpolyaspartamideChemical structurePharmaceutical ScienceReceptors Cell SurfaceConjugated systemDeoxycytidineDrug Delivery SystemsFolic AcidCell Line Tumorfolate-mediated targetingExtracellularHumansProdrugsIncubationPolyhydroxyethyl MethacrylateDrug CarriersDose-Response Relationship DrugChemistrypolymeric conjugateFolate Receptors GPI-AnchoredSuccinatesHydrogen-Ion ConcentrationGemcitabineIn vitroBiochemistryCell cultureCarrier ProteinsMacromoleculeConjugateInternational journal of pharmaceutics
researchProduct